Clinical trial application submitted for a next generation pain killer.

Daewoong Pharmaceutical has submitted an application to conduct clinical trials for a newly developed next generation neural pain killer.

Although other pharmaceutical companies such as Merck and GSK have developed similar pain killers, DWP05195 differs in that it directly attacks the neural cells causing the disorder making its efficacy much higher than the other pain killers currently on the market.

Patients suffering from diseases which are accompanied by these types of pains caused by neural cells endure an insurmountable amount of pain. Although it is not exactly known it is estimated that approximately 7% of the world’s population (26 million) suffer from such neurological diseases.
 
The current neurological pain killers on the market were developed for patients suffering from epilepsy or clinical depression. Therefore they are not so effective in treating other neurological disorders and are also known to have adverse effects on the central nervous system. However there are no other drugs that are currently on the market while the sales of current products continue to increase. It estimated that sales will rise from 2.8 million USD in 2008 to 7.6 million USD in 2015. When DWP05195 does hit the market, it is expected to be a global hit.

Plans call for the first phase of the clinical research trials are set to take place at Seoul National University Hospital on participants without any diseases to test for safety and the second phase is set to involve patients with neurological diseases to test for effectiveness.
 
In additional to establishing DWP05195 as a global pharmaceutical product, Daewoong Pharmaceutical has plans to work together with various pharmaceutical companies to co-develop similar products while simultaneously conducting the clinical trials.